A study published in May 2020 revealed the extent of the impact that the COVID-19 could have on the economy in Italy based on three different scenarios (soft, intermediate, and hard). The average EBITDA margin of pharmaceutical manufacturers in Italy could increase under a soft and an intermediate scenario. On the other hand, it was estimated that the EBITDA could decrease to ten percent based on a hard scenario.
The scenarios are described by the source as follows: soft scenario includes 1.5 months of lockdown; intermediate scenario assumes a longer period of shut down within a range of 2 to 4 months with some activities that will reopen before others as a consequence of a new wave of contagion; worst case scenario assumes a lockdown of up 6 months.
Covid-19 forecast impact on EBITDA margin of Italy's pharmaceutical manufacturers as of 2020, by scenario
Soft scenario: incorporates the lockdown of 1.5 months that most of the activities have passed through and assuming that the curve of contagion will keep decreasing avoiding a new lockdown period; this will determine a remarkable and fast boost of business confidence even though some sectors will have some trouble to come back to previous business levels as the demand
for highly discretionary goods and services remain capped. The macroeconomic emergency measures will turn to be effective to restore confidence and companies will manage to limit the negative economic consequences to the FY2020. Export driven sectors will benefit from the rebound in the international trade.
Intermediate scenario: assumes a longer lockdown period (total lockdown period ranges from 2 to 4 months); after the initial lockdown release, a second wave of COVID-19 contagion will hit the country making necessary to re-impose some lockdown measures. According to the aforementioned paper of the Imperial College of London “Report 20: Using mobility to estimate the transmission intensity of the virus in Italy: A subnational analysis with future scenarios”, if the population will not respect social distancing, Italy could experience a significant amount of new COVID-19 cases with just 20% of mobility increase; thus, the introduction of new lockdown measures must be taken into consideration; the economic recovery will be very slow and not homogenous. The loss of confidence from consumers due to a second wave of contagion will be extremely dangerous
for the economy.
Hard scenario: considers the possibility that an effective cure will not be ready for at least 12 months or even that a vaccine will not be found at all. People will learn to live with virus and several waves will affect the world in the future. The Agency assumes that after the initial ease of the lockdown measures, the number of positive cases will pick-up again, forcing the authorities to re-impose the precautionary measures for a longer period (total lockdown period up to 6 months). Eventually, the entire economic system will be completely transformed and a severe recession will hit the entire world; some sectors wil never operate in the way they use to do before the emergency and the “normal” habits of people will change permanently. The economic measures enforced worldwide will have very limited effect and a significant reduction of the international trade is expected. Export driven sectors will not benefit as the target market will shift to the internal one.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.
Cerved Rating Agency. (May 28, 2020). Covid-19 forecast impact on EBITDA margin of Italy's pharmaceutical manufacturers as of 2020, by scenario [Graph]. In Statista. Retrieved May 22, 2022, from https://www.statista.com/statistics/1181824/ebitda-margin-of-pharmaceutical-manufacturers-italy/
Cerved Rating Agency. "Covid-19 forecast impact on EBITDA margin of Italy's pharmaceutical manufacturers as of 2020, by scenario." Chart. May 28, 2020. Statista. Accessed May 22, 2022. https://www.statista.com/statistics/1181824/ebitda-margin-of-pharmaceutical-manufacturers-italy/
Cerved Rating Agency. (2020). Covid-19 forecast impact on EBITDA margin of Italy's pharmaceutical manufacturers as of 2020, by scenario. Statista. Statista Inc.. Accessed: May 22, 2022. https://www.statista.com/statistics/1181824/ebitda-margin-of-pharmaceutical-manufacturers-italy/
Cerved Rating Agency. "Covid-19 Forecast Impact on Ebitda Margin of Italy's Pharmaceutical Manufacturers as of 2020, by Scenario." Statista, Statista Inc., 28 May 2020, https://www.statista.com/statistics/1181824/ebitda-margin-of-pharmaceutical-manufacturers-italy/
Cerved Rating Agency, Covid-19 forecast impact on EBITDA margin of Italy's pharmaceutical manufacturers as of 2020, by scenario Statista, https://www.statista.com/statistics/1181824/ebitda-margin-of-pharmaceutical-manufacturers-italy/ (last visited May 22, 2022)